Leveraging PEPFAR- and Global Fund–Supported Laboratory Network for Integrated Disease Testing: Lessons From Integrated HIV, Tuberculosis, and COVID-19 Testing in Nigeria
The Nigeria Centre for Disease Control and Prevention, as part of the strategic approach to the COVID-19 outbreak response in Nigeria, coordinated the implementation of an integrated disease testing (IDT) strategy with support from multiple partners. This involved adaptation of existing US President's Emergency Plan for AIDS Relief (PEPFAR)- and Global Fund-supported molecular laboratory networks and integration of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) testing into these. This enabled the country to provide large-scale testing and rapid return of results for SARS-CoV-2 from 2020 to 2022. IDT provided an opportunity for mainstreaming outbreak response into existing human immunodeficiency virus (HIV) and tuberculosis testing laboratories. Lessons learned from this have informed the adoption of IDT across the country laboratory network as an efficient approach to multiple disease testing and pandemic preparedness and response in Nigeria.
Authors
- Chika Onwuamah (ORCID: https://orcid.org/0000-0002-5111-1822)
- Chidozie Ezechukwu (ORCID: https://orcid.org/0000-0003-3709-3792)
- Emmanuel Agogo (ORCID: https://orcid.org/0000-0002-3570-3254)
- Israel Audu
- Mahesh Swaminathan (ORCID: https://orcid.org/0000-0001-5827-3245)
- Christopher Chime
- Catherine Godfrey (ORCID: https://orcid.org/0000-0002-5797-7950)
- Catherine Okoi (ORCID: https://orcid.org/0000-0003-2412-852X)
- Olajumoke Babatunde
- Chukwuma Anyaike (ORCID: https://orcid.org/0000-0002-3570-5831)
- Mary Adetinuke Boyd (ORCID: https://orcid.org/0000-0001-6565-680X)
- Chikwe Ihekweazu (ORCID: https://orcid.org/0000-0003-0659-0833)
- Patricia Hall (ORCID: https://orcid.org/0000-0002-9107-1730)
- Aminu Suleiman
- Nicole Espy (ORCID: https://orcid.org/0000-0002-4805-189X)
- Akudo Ikpeazu (ORCID: https://orcid.org/0000-0002-0654-2201)
- Dhamari Naidoo (ORCID: https://orcid.org/0000-0002-8565-4227)
- Nnaemeka Ndodo (ORCID: https://orcid.org/0000-0003-2792-8311)
- Celestina Obiekea (ORCID: https://orcid.org/0000-0003-2355-5917)
- Jibrin Kama
- McPaul Okoye (ORCID: https://orcid.org/0000-0001-8745-8441)
- Clement Zeh
- Philippe Chebu (ORCID: https://orcid.org/0009-0008-7492-670X)
- Nnaemeka C. Iriemenam (ORCID: https://orcid.org/0000-0003-2187-8894)
- Nwando Mba
- Obinna Nnadozie
- I. C. Okoli (ORCID: https://orcid.org/0000-0002-8988-9496)
- Ifedayo Adetifa (ORCID: https://orcid.org/0000-0003-2556-9407)
- Anthony Ahumibe (ORCID: https://orcid.org/0000-0002-4651-4424)
- Kingsley Chike Madubuike
- Afolabi Akinpelu (ORCID: https://orcid.org/0000-0002-1837-6255)
- C A Okolo
- Kingsley Njoku
- Victor Obianeri
- Chibuzor Eneh
Institutions
- FIND (CH)
- Centers for Disease Control and Prevention (US)
- World Health Organization - Pakistan (PK)
- United States Department of Defense (US)
- United States Department of State (US)
- Federal Ministry of Health (NG)
- AIDS United (US)
- United States Agency for International Development (US)
- London School of Hygiene & Tropical Medicine (GB)
- Clinton Health Access Initiative (US)
- Management Sciences for Health (US)
- Centers for Disease Control and Prevention (UG)
- World Health Organization (CH)
- Reed Medical (United Kingdom) (GB)
- AIDS Prevention Initiative in Nigeria (NG)
- Institute of Human Virology (NG)
- World Health Organization - Nigeria (NG)
- Federal Medical Centre (NG)
- Nigeria Centre for Disease Control (NG)
- National Agency for the Control of AIDS (NG)
- Nigerian Institute of Medical Research (NG)
Publication Details
- Journal
- The Journal of Infectious Diseases
- Published
- 2025-06-23
- DOI
- https://doi.org/10.1093/infdis/jiaf334
- Citations
- 1
- Primary Topic
- SARS-CoV-2 detection and testing
- Type
- article
- Field-Weighted Citation Impact
- 1.40